Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan, Risk-Adapted Radiation, and Dose-Intensive Chemotherapy in Medulloblastoma and Supratentorial PNET
NCT00003211Phase 2Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Oct 1996
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of topotecan in medulloblastoma and supratentorial primitive neuroectodermal tumor (sPNET) (2 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Response rate to topotecan. Started Oct 1996; status: completed.
02
Drugs
topotecan
03
Conditions
medulloblastomasupratentorial primitive neuroectodermal tumor (sPNET)
Beyond the preview
Go deeper on NCT00003211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003211.